Major Revision of USP Chapter <1724> Semisolid Drug Products Performance Tests Published for Comment
Recommendation

Thursday, 29 October 2026 9 .00 - 14.00 h
Practical Approaches for Assessing the Risks of Impurities
In the current Pharmacopeial Forum, PF 48(3), a major revision of USP general chapter <1724> Semisolid Drug Products—Performance Tests is being proposed. This proposal is based on the version of the chapter official as of August 01, 2013.
The scope of the currently valid chapter is "to provide general information for performance testing of semisolid drug products, various types of equipment employed for such testing, and potential applications of the performance testing". Compared to the currently valid version, the scope of the new draft has been expanded. It also includes in vitro release test (IVRT) as well as in vitro permeation test (IVPT) methods, with discussions on experimental design, method development, and validation.
According to the briefing notes, the proposal further includes "new information on appropriate contexts of use for IVRT and IVPT studies, and a guide for selecting an appropriate test method (IVRT or IVPT) depending upon the goal of the experiment." In addition, the text contains "revise information related to test equipment for IVRT and IVPT studies, with general discussions on setup and qualification considerations for vertical diffusion cells, immersion cells, and flow-through diffusion cells."
The text was also adapted and expanded in other parts. All these changes are noticeable in a more detailed structuring of the subchapters. The chapter is now divided into the following sections:
- Scope
- Introduction
- In vitro release test (IVRT)
- In vitro permeation test (IVPT)
- Equipment
The draft of the revised chapter is available on PF Online. (Please note: a one-time registration is required to access the Pharmacopeial Forum. Comments can be submitted until July 31, 2022.
Related GMP News
21.10.2026EMA Updates Information Page on Bioequivalence Guidelines
21.10.2026BP Publishes new Draft Texts
21.10.2026FDA Identifies Critical Deficiencies in Analytical Testing and CGMP Oversight
07.10.2026Analytical Quality Group Developments May through August 2026
07.10.2026Two New FDA Warning Letters Put OOS Investigations in Focus
07.10.2026Pharmeuropa: Revision Proposed for Chapter 2.5.32 on Coulometric Karl Fischer Water Determination

